HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
 Help
Order: Signal: Tickers:
Filters
Overview Valuation Financial Ownership Performance Technical Custom Charts Tickers Basic TA News Snapshot Maps Stats
Total: 200 #11 Type: candle | line | technical    Timeframe: daily | intraday    Auto Refresh: 3min | off
TickerDUO [NASD]
CompanyFangdd Network Group Ltd.
CountryChina
IndustryReal Estate Services
Market Cap8.28MEPS (ttm)-469.22
P/E-EPS this Y-424.00%
Forward P/E-EPS next Y-
PEG-EPS past 5Y-14.30%
P/S0.06EPS next 5Y-
P/B0.01EPS Q/Q-540.00%
Dividend-Sales Q/Q-87.00%
Insider Own17.39%Inst Own0.70%
Insider Trans0.00%Inst Trans-8.98%
Short Float4.17%EarningsAug 31/b
Analyst Recom3.00Target Price-
Avg Volume115.43K52W Range1.42 - 26.79
Sep-08-22 07:30AMFangDD to Hold an Extraordinary General Meeting of Shareholders on October 14, 2022 GlobeNewswire
Aug-31-22 08:17AMFangDD Announces Board and Management Changes GlobeNewswire
Aug-31-22 08:00AMFangDD Reports First Half 2022 Unaudited Financial Results GlobeNewswire
Aug-04-22 08:00AMFangDD Provides Clarification on Dismissal of KPMG GlobeNewswire
Aug-01-22 08:00AMFangDD Announces Change of Independent Registered Public Accounting Firm GlobeNewswire
Jul-19-22 07:45AMFangDD Announces Board and Committee Changes GlobeNewswire
Jun-23-22 08:35AMFangDD Regains Compliance with Nasdaq Minimum Bid Price Requirement GlobeNewswire
Jun-08-22 07:54AMIs Fangdd Network Group Ltd.'s (NASDAQ:DUO) Shareholder Ownership Skewed Towards Insiders? Simply Wall St.
May-27-22 07:49AMFangDD Announces Plan to Implement ADS Ratio Change GlobeNewswire
May-18-22 10:10AMFangdd Announces Management and Board Changes GlobeNewswire
TickerNMRD [NASD]
CompanyNemaura Medical Inc.
CountryUSA
IndustryMedical Devices
Market Cap44.30MEPS (ttm)-0.61
P/E-EPS this Y-111.40%
Forward P/E-EPS next Y26.60%
PEG-EPS past 5Y-51.00%
P/S88.60EPS next 5Y-
P/B-EPS Q/Q-14.10%
Dividend-Sales Q/Q-
Insider Own59.15%Inst Own3.60%
Insider Trans0.00%Inst Trans-0.93%
Short Float0.97%Earnings-
Analyst Recom2.00Target Price10.83
Avg Volume8.14K52W Range1.70 - 6.88
Sep-06-22 08:30AMNemaura Medical to Present at the 24th Annual H.C. Wainwright Global Investment Conference GlobeNewswire
Aug-26-22 09:03AM10 Stock Picks of Late Julian Robertsons Tiger Management Insider Monkey
Aug-15-22 09:45AMNemaura Medical, Inc. (NMRD) Reports Q1 Loss, Lags Revenue Estimates Zacks
Aug-15-22 08:30AMNemaura Medical Reports Fiscal First Quarter 2023 Results and Provides Business Update GlobeNewswire
Aug-08-22 08:17AMIBN (InvestorBrandNetwork) Announces Latest Episode of The Bell2Bell Podcast Featuring Dr. Faz Chowdhury, CEO of Nemaura Medical Inc. GlobeNewswire
Jul-21-22 08:00AMNemaura Medical Granted UK Trademark Meta Score, a Digital Biomarker Term for its Metabolic Health Program GlobeNewswire
Jun-30-22 08:00AMNemaura Medical Reports Financial Results and Provides Business Update for the Fiscal Year Ended March 31, 2022 GlobeNewswire
Jun-02-22 03:46PMJulian Robertsons Hedge Fund Portfolio in 2022: 7 Latest Stock Picks Insider Monkey
May-23-22 06:30AMNemaura Medical Strengthens Balance Sheet with Further Non-Dilutive Funding GlobeNewswire
May-19-22 08:00AMNemaura Medical to Present at the H.C. Wainwright Global Hybrid Investment Conference GlobeNewswire
TickerSTBX [NASD]
CompanyStarbox Group Holdings Ltd.
CountryMalaysia
IndustryInternet Content & Information
Market Cap153.00MEPS (ttm)0.06
P/E56.67EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S25.63EPS next 5Y-
P/B53.97EPS Q/Q-
Dividend-Sales Q/Q2352.90%
Insider Own64.44%Inst Own-
Insider Trans-Inst Trans-
Short Float-Earnings-
Analyst Recom-Target Price-
Avg Volume8.23M52W Range3.39 - 46.21
Aug-25-22 01:00PMStarbox Group Holdings Ltd. Announces Closing of US$21.5 million Initial Public Offering Including Partial Exercise of Over-Allotment Option GlobeNewswire
Aug-22-22 08:00PMStarbox Group Holdings Ltd. Announces Pricing of US$20 million Initial Public Offering GlobeNewswire
TickerNEXI [NASD]
CompanyNexImmune, Inc.
CountryUSA
IndustryBiotechnology
Market Cap30.18MEPS (ttm)-2.68
P/E-EPS this Y-65.20%
Forward P/E-EPS next Y39.10%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B0.52EPS Q/Q-28.70%
Dividend-Sales Q/Q-
Insider Own11.60%Inst Own34.60%
Insider Trans27.58%Inst Trans-12.94%
Short Float2.95%Earnings-
Analyst Recom1.70Target Price3.50
Avg Volume1.16M52W Range1.01 - 18.78
Sep-08-22 07:00AMSelexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders Business Wire
Sep-03-22 08:19AMBullish insiders bet US$1.7m on NexImmune, Inc. (NASDAQ:NEXI) Simply Wall St.
Aug-15-22 04:05PMNexImmune Reports Second Quarter 2022 Financial Results and Highlights FDA Clearance of IND for NEXI-003 for the Treatment of HPV-Related Cancers GlobeNewswire
Jul-20-22 11:42AMBiotech Stock Roundup: APLS, NVAX Gain on Updates, INCYs Regulatory News & More Zacks
Jul-18-22 08:20AMCan NexImmune (NASDAQ:NEXI) Afford To Invest In Growth? Simply Wall St.
Jul-15-22 11:00AMNexImmune (NEXI) IND Gets Clearance for HPV-Related Cancer Drug Zacks
Jul-14-22 04:09PMNexImmune Announces IND Clearance by the US FDA for NEXI-003 for the Treatment of HPV-Related Cancers GlobeNewswire
Jun-10-22 12:00PMWhat Makes NexImmune, Inc. (NEXI) a New Buy Stock Zacks
May-12-22 04:01PMNexImmune Reports First Quarter 2022 Financial Results and Provides Business Updates GlobeNewswire
May-10-22 04:01PMNexImmune, Yale, and JDRF Enter into Research Partnership for Type 1 Diabetes GlobeNewswire
TickerRETA [NASD]
CompanyReata Pharmaceuticals, Inc.
CountryUSA
IndustryBiotechnology
Market Cap1.08BEPS (ttm)-8.37
P/E-EPS this Y-2.20%
Forward P/E-EPS next Y8.50%
PEG-EPS past 5Y-
P/S107.58EPS next 5Y-
P/B14.40EPS Q/Q-0.70%
Dividend-Sales Q/Q-63.60%
Insider Own0.10%Inst Own89.70%
Insider Trans0.00%Inst Trans2.09%
Short Float15.53%EarningsAug 08/b
Analyst Recom1.80Target Price50.67
Avg Volume674.01K52W Range18.47 - 114.80
Sep-07-22 11:30AMReata Pharmaceuticals, Inc. (RETA) Up 4.7% Since Last Earnings Report: Can It Continue? Zacks
Sep-06-22 04:51PMReata Pharmaceuticals Announces Participation in the Citi 17th Annual BioPharma Conference Business Wire
Aug-14-22 08:14AMTime To Worry? Analysts Just Downgraded Their Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Outlook Simply Wall St.
Aug-09-22 12:04PMFDA Pushes Decision Date For Reata's Genetic Neuromuscular Disease Candidate Benzinga
Aug-09-22 11:56AMReata (RETA) Q2 Earnings Miss, Revenues Down Y/Y, Stock Down Zacks
Aug-09-22 06:45AMReata Pharmaceuticals Announces Three Month Extension of the Review Period for New Drug Application for Omaveloxolone for the Treatment of Friedreichs Ataxia Business Wire
Aug-08-22 10:16AMWhy Reata Pharma Shares Are Trading Lower After Q2 Earnings Update? Benzinga
Aug-08-22 07:55AMReata Pharmaceuticals, Inc. (RETA) Reports Q2 Loss, Lags Revenue Estimates Zacks
Aug-08-22 06:45AMReata Pharmaceuticals, Inc. Announces Second Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs Business Wire
Aug-01-22 06:45AMReata Pharmaceuticals, Inc. to Report Second Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on August 8, 2022 Business Wire
TickerBIAF [NASD]
CompanybioAffinity Technologies, Inc.
CountryUSA
IndustryDiagnostics & Research
Market Cap8.74MEPS (ttm)-
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S6692.19EPS next 5Y-
P/B-EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own-Inst Own-
Insider Trans-Inst Trans-
Short Float-Earnings-
Analyst Recom-Target Price-
Avg Volume10.56M52W Range5.08 - 15.55
Sep-06-22 01:54PMWallachBeth Capital Announces Closing Of bioAffinity Technologies, Inc. $7.8 Million Initial Public Offering PR Newswire
Sep-06-22 11:28AMbioAffinity Technologies, Inc. Announces Closing of $7.8 Million Initial Public Offering Business Wire
Sep-01-22 12:32PMWallachBeth Capital Announce Pricing Of bioAffinity Technologies IPO At $6.125 Per Unit PR Newswire
Sep-01-22 08:15AMbioAffinity Technologies Announces Pricing of IPO Business Wire
TickerCTV [NYSE]
CompanyInnovid Corp.
CountryUSA
IndustryAdvertising Agencies
Market Cap506.37MEPS (ttm)0.77
P/E4.77EPS this Y-991.10%
Forward P/E-EPS next Y40.00%
PEG-EPS past 5Y-
P/S4.67EPS next 5Y-
P/B2.30EPS Q/Q102.30%
Dividend-Sales Q/Q45.20%
Insider Own4.80%Inst Own63.00%
Insider Trans0.00%Inst Trans4.96%
Short Float0.87%EarningsAug 10/b
Analyst Recom2.00Target Price5.67
Avg Volume322.49K52W Range1.62 - 10.00
Aug-30-22 04:30PMInnovid to Present at Evercore's 2nd Annual Technology Conference on September 7, 2022 PR Newswire
Aug-13-22 08:31AMInnovid Corp. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year Simply Wall St.
Aug-10-22 07:00AMInnovid Reports Second Quarter 2022 Financial Results PR Newswire
Jul-21-22 08:30AMInnovid to Announce Second Quarter 2022 Financial Results on August 10th, 2022 PR Newswire
Jul-15-22 06:17AMWhat Kind Of Investors Own Most Of Innovid Corp. (NYSE:CTV)? Simply Wall St.
Jul-11-22 07:30AMInnovid to Present at Upcoming July Investor Events on July 12, 2022 PR Newswire
Jul-08-22 07:30AMInnovid Announces Changes to its Board of Directors PR Newswire
Jun-22-22 07:59AMThe past year for Innovid (NYSE:CTV) investors has not been profitable Simply Wall St.
Jun-07-22 07:30AMInnovid to Participate in MKM Virtual Ad-Tech Summit PR Newswire
Jun-03-22 08:30AMAdImpact Partners with Innovid to Measure Political TV Advertising Across Linear & CTV Business Wire
TickerGRFX [AMEX]
CompanyGraphex Group Limited
CountryHong Kong
IndustryOther Industrial Metals & Mining
Market Cap63.41MEPS (ttm)-
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S0.17EPS next 5Y-
P/B0.15EPS Q/Q-
Dividend-Sales Q/Q-10.70%
Insider Own-Inst Own0.01%
Insider Trans-Inst Trans-
Short Float-Earnings-
Analyst Recom-Target Price-
Avg Volume2.00M52W Range1.50 - 4.66
Aug-31-22 07:01AMGraphex Group Announces Interim Financial Highlights and Global Expansion Progress GlobeNewswire
Aug-26-22 04:15PMGraphex Group Limited Announces Full Exercise of Over-Allotment Option in Underwritten Public Offering GlobeNewswire
Aug-22-22 09:29AMGraphex Technologies Highlights U.S. Expansion Progress and Outlines Business Strategy GlobeNewswire
Aug-19-22 04:05PMGraphex Group Limited Announces Closing of Upsized $11.7 Million Public Offering and NYSE American Listing GlobeNewswire
Aug-16-22 07:08PMGraphex Group Limited Announces Pricing of Upsized $11.7 Million Public Offering and NYSE American Listing GlobeNewswire
TickerQH [NASD]
CompanyQuhuo Limited
CountryChina
IndustrySoftware - Application
Market Cap16.11MEPS (ttm)-22.25
P/E-EPS this Y131.20%
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S0.03EPS next 5Y-
P/B0.02EPS Q/Q321.70%
Dividend-Sales Q/Q-46.20%
Insider Own24.76%Inst Own0.10%
Insider Trans0.00%Inst Trans-14.53%
Short Float0.31%Earnings-
Analyst Recom2.00Target Price30.00
Avg Volume74.93K52W Range2.62 - 31.40
Sep-07-22 06:00AMQuhuo Announces Changes to Board of Directors PR Newswire
Aug-31-22 06:00AMQuhuo Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement PR Newswire
Aug-13-22 09:30AMWhat Is The Ownership Structure Like For Quhuo Limited (NASDAQ:QH)? Simply Wall St.
Aug-09-22 07:00AMQuhuo Announces Plan to Implement ADS Ratio Change PR Newswire
Jul-18-22 07:00PMQuhuo Announces Management Change PR Newswire
May-19-22 07:00PMQuhuo Announces Receipt of Nasdaq Notification Regarding Late Filing of Annual Report on Form 20-F GlobeNewswire
May-12-22 09:54AMDeutsche Banks Depositary Receipts Virtual Investor Conference presentations now available for on-demand viewing GlobeNewswire
May-08-22 08:30PMInternational companies to host live webcasts at Deutsche Banks Depositary Receipts Virtual Investor Conference on May 10th and 11th, 2022 GlobeNewswire
May-05-22 08:58AMInternational companies to host live webcasts at Deutsche Banks Depositary Receipts Virtual Investor Conference on May 10th and 11th, 2022 GlobeNewswire
Mar-03-22 06:00AMQuhuo Announces Receipt of Nasdaq Notice GlobeNewswire
TickerAVTX [NASD]
CompanyAvalo Therapeutics, Inc.
CountryUSA
IndustryBiotechnology
Market Cap45.96MEPS (ttm)-7.83
P/E-EPS this Y12.50%
Forward P/E-EPS next Y19.30%
PEG-EPS past 5Y14.70%
P/S12.09EPS next 5Y-
P/B-EPS Q/Q35.50%
Dividend-Sales Q/Q-70.60%
Insider Own6.08%Inst Own61.50%
Insider Trans67.65%Inst Trans-10.97%
Short Float1.15%Earnings-
Analyst Recom2.00Target Price31.75
Avg Volume54.54K52W Range2.42 - 34.92
Sep-06-22 07:00AMAvalo Advances BTLA Agonist Fusion Protein (AVTX-008) to IND-enabling Stage GlobeNewswire
Sep-01-22 07:00AMAvalo to Present at the H.C. Wainwright Global Investment Conference GlobeNewswire
Aug-11-22 04:01PMAvalo Therapeutics Announces Board Changes GlobeNewswire
Aug-09-22 10:39AMThese 2 Penny Stocks Are Poised for a Big Rally, Says Oppenheimer TipRanks
Aug-04-22 07:30AMAvalo Reports Second Quarter 2022 Financial Results and Provides Business Updates GlobeNewswire
Aug-02-22 07:30AMAvalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II) GlobeNewswire
Aug-01-22 07:00AMAvalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics GlobeNewswire
Jul-06-22 04:05PMAvalo Therapeutics Announces One-for-Twelve Reverse Stock Split GlobeNewswire
Jun-20-22 12:10PMInvestors in Avalo Therapeutics (NASDAQ:AVTX) have unfortunately lost 90% over the last three years Simply Wall St.
Jun-02-22 07:30AMAvalo to Present at the 2022 Jefferies Healthcare Conference GlobeNewswire
prev1234567 ... 10 ... 20next
affiliate • advertise • contact • privacy • help
Do Not Sell My Data • Privacy Settings
Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2022 FINVIZ.com. All Rights Reserved.